182 related articles for article (PubMed ID: 15359628)
1. Risk assessment in chronic myelomonocytic leukemia (CMML).
Germing U; Kündgen A; Gattermann N
Leuk Lymphoma; 2004 Jul; 45(7):1311-8. PubMed ID: 15359628
[TBL] [Abstract][Full Text] [Related]
2. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
3. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.
González-Medina I; Bueno J; Torrequebrada A; López A; Vallespí T; Massagué I
Leuk Res; 2002 Sep; 26(9):821-4. PubMed ID: 12127557
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Onida F; Kantarjian HM; Smith TL; Ball G; Keating MJ; Estey EH; Glassman AB; Albitar M; Kwari MI; Beran M
Blood; 2002 Feb; 99(3):840-9. PubMed ID: 11806985
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
6. Problems in the classification of CMML--dysplastic versus proliferative type.
Germing U; Gattermann N; Minning H; Heyll A; Aul C
Leuk Res; 1998 Oct; 22(10):871-8. PubMed ID: 9766745
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
8. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
10. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
Khan M; Muzzafar T; Kantarjian H; Badar I; Short N; Wang X; Chamoun K; Jain P; DiNardo C; Pemmaraju N; Bose P; Borthakur G; Cortes J; Verstovsek S; Garcia-Manero G; Estrov Z
Ann Hematol; 2018 Jul; 97(7):1183-1191. PubMed ID: 29557496
[TBL] [Abstract][Full Text] [Related]
11. Models of Prognostication in Chronic Myelomonocytic Leukemia.
Onida F
Curr Hematol Malig Rep; 2017 Dec; 12(6):513-521. PubMed ID: 29064026
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
13. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia.
Storniolo AM; Moloney WC; Rosenthal DS; Cox C; Bennett JM
Leukemia; 1990 Nov; 4(11):766-70. PubMed ID: 2232890
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic risk stratification in chronic myelomonocytic leukemia.
Such E; Cervera J; Costa D; Solé F; Vallespí T; Luño E; Collado R; Calasanz MJ; Hernández-Rivas JM; Cigudosa JC; Nomdedeu B; Mallo M; Carbonell F; Bueno J; Ardanaz MT; Ramos F; Tormo M; Sancho-Tello R; del Cañizo C; Gómez V; Marco V; Xicoy B; Bonanad S; Pedro C; Bernal T; Sanz GF
Haematologica; 2011 Mar; 96(3):375-83. PubMed ID: 21109693
[TBL] [Abstract][Full Text] [Related]
17. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
19. Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution.
Nösslinger T; Reisner R; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Leuk Res; 2001 Sep; 25(9):741-7. PubMed ID: 11489467
[TBL] [Abstract][Full Text] [Related]
20. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia.
Rivera Duarte A; Armengol Alonso A; Sandoval Cartagena E; Tuna Aguilar E
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):532-538. PubMed ID: 28842140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
